ProShare Advisors LLC Raises Stock Holdings in Zoetis Inc. $ZTS

ProShare Advisors LLC lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 6.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 116,738 shares of the company’s stock after acquiring an additional 7,211 shares during the period. ProShare Advisors LLC’s holdings in Zoetis were worth $18,205,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Lindbrook Capital LLC increased its stake in Zoetis by 1.8% in the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company’s stock valued at $612,000 after purchasing an additional 65 shares during the period. Scott & Selber Inc. grew its holdings in shares of Zoetis by 0.6% during the second quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock worth $1,817,000 after buying an additional 67 shares during the last quarter. Secure Asset Management LLC increased its position in Zoetis by 2.9% in the 2nd quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock valued at $382,000 after acquiring an additional 68 shares during the period. Moment Partners LLC raised its stake in Zoetis by 3.2% during the 2nd quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock valued at $367,000 after acquiring an additional 72 shares during the last quarter. Finally, CVA Family Office LLC lifted its position in Zoetis by 6.7% during the 2nd quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock worth $183,000 after acquiring an additional 74 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS stock opened at $120.09 on Wednesday. The firm has a 50 day moving average of $142.82 and a 200-day moving average of $152.16. The company has a market cap of $52.92 billion, a price-to-earnings ratio of 20.67, a PEG ratio of 2.31 and a beta of 0.90. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12-month low of $117.26 and a 12-month high of $181.85.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same period in the previous year, the business earned $1.58 earnings per share. Zoetis’s quarterly revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.7%. Zoetis’s dividend payout ratio is presently 33.67%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ZTS. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Piper Sandler upped their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Stifel Nicolaus set a $140.00 target price on shares of Zoetis in a report on Tuesday, November 4th. Finally, Morgan Stanley cut their price target on shares of Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a report on Monday. Five investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Zoetis currently has a consensus rating of “Moderate Buy” and a consensus target price of $182.50.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.